Renovaro Inc. (NASDAQ:RENB) Major Shareholder Sells $93,000.00 in Stock

Renovaro Inc. (NASDAQ:RENBGet Free Report) major shareholder Anderson Wittekind William sold 60,000 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $1.55, for a total transaction of $93,000.00. Following the transaction, the insider now directly owns 974,275 shares in the company, valued at approximately $1,510,126.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Anderson Wittekind William also recently made the following trade(s):

  • On Wednesday, July 3rd, Anderson Wittekind William sold 50,000 shares of Renovaro stock. The shares were sold at an average price of $1.51, for a total transaction of $75,500.00.
  • On Monday, July 1st, Anderson Wittekind William sold 60,000 shares of Renovaro stock. The stock was sold at an average price of $1.56, for a total transaction of $93,600.00.
  • On Thursday, June 27th, Anderson Wittekind William sold 14,671 shares of Renovaro stock. The stock was sold at an average price of $1.50, for a total transaction of $22,006.50.
  • On Tuesday, June 25th, Anderson Wittekind William sold 20,000 shares of Renovaro stock. The stock was sold at an average price of $1.58, for a total value of $31,600.00.
  • On Friday, June 14th, Anderson Wittekind William sold 50,000 shares of Renovaro stock. The shares were sold at an average price of $1.58, for a total value of $79,000.00.

Renovaro Stock Performance

RENB opened at $1.52 on Thursday. Renovaro Inc. has a twelve month low of $0.48 and a twelve month high of $5.25. The business has a 50 day moving average price of $1.40 and a 200 day moving average price of $2.50. The firm has a market cap of $224.22 million, a P/E ratio of -1.95 and a beta of 0.60.

Renovaro (NASDAQ:RENBGet Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.08) earnings per share for the quarter.

Institutional Investors Weigh In On Renovaro

A number of hedge funds have recently bought and sold shares of RENB. SG Americas Securities LLC bought a new position in shares of Renovaro in the first quarter worth about $46,000. Tidal Investments LLC bought a new stake in Renovaro during the 1st quarter valued at approximately $98,000. Finally, Vanguard Group Inc. grew its holdings in Renovaro by 904.0% in the 1st quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock valued at $10,379,000 after buying an additional 3,526,565 shares during the last quarter. 71.41% of the stock is currently owned by institutional investors.

Renovaro Company Profile

(Get Free Report)

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.

Featured Stories

Receive News & Ratings for Renovaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovaro and related companies with MarketBeat.com's FREE daily email newsletter.